PMVP
PMV Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.26
+3.72%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$1.24
From 52W high−30.28%
Volume195927.00
Market cap$94.77M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$1.24
From 52W high
−30.28%
Volume
195927.00
Market cap
$94.77M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.2x
P/E (TTM)
—
RSI (14)
42.5
MomentumView details →
1D Return
+3.72%
YTD Return
+2.34%
SummaryUpdated Jun 1, 2026
PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) is a precision oncology company founded in 2013 and headquartered in Cranbury, New Jersey. Originally incorporated as PJ Pharmaceuticals, Inc., the company changed its name to PMV Pharmaceuticals in July 2013 and went public in September 2020. PMV focuses on developing small molecule therapies that target specific mutations in the p53 protein, which is often called the "guardian of the genome" due to its critical role in preventing cancer development. The company operates in the highly specialized field of precision oncology, where treatments are designed to target specific genetic mutations found in cancer patients.
Similar companies
Latest newsMore news →
PMV Pharmaceuticals, Inc. appointed Matthew Eckler as a director effective October 1, 2026, granting him an initial stock option award for 84,000 shares and an annual option to purchase 42,000 shares.15d agoPMV Pharmaceuticals announced the commencement of an underwritten public offering of common stock and warrants, including pre-funded warrants, to raise capital.49d ago